arrow
M

María Reig

hospital clinic barcelona
H指数:60
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy

接受联合放射免疫治疗的肝细胞癌患者来源新抗原的免疫原性

2026-03-180
OA
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update

用于预后预测和治疗建议的BCLC策略: 2025更新

2025-10-270
PRE
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy

突破接受免疫治疗晚期HCC患者进入重症监护的障碍

2025-08-120
OAAI
Corrigendum to” Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes,” [Eur J Cancer 2025 May 15:221:115404.]

勘误:“接受免疫治疗的肝细胞癌患者的心血管不良事件:合并症和临床结局的影响”,[Eur J Cancer 2025 May 15:221:115404.]

2025-06-120
PRE
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes

接受免疫治疗的原发性肝癌患者的心脏不良事件:合并症和临床结局的影响

2025-05-010
PRE
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

HIMALAYA研究五-year总体生存率更新:曲美木单抗联合度伐利尤单抗治疗不可切除性HCC

2025-04-110
OAAI
Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus (vol 14, pg 134, 2024)
2025-03-010
PRE
Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study

Fostrox(fostroxacitabine bralpamide)联合仑伐替尼治疗既往接受免疫联合疗法后进展的局部晚期不可切除或转移性肝细胞癌(HCC)患者:一项多中心 Ib/IIa 期研究的结果

2024-09-010
PRE